#China #Hong Kong #Cancer Treatment #Akeso #Cadonilimab

Cadonilimab Demonstrates Significant Efficacy in Cervical Cancer Treatment

In a groundbreaking revelation at the 27th European Congress on Gynaecological Oncology (ESGO 2026), Akeso, Inc. unveiled the long-term results of their Phase II clinical trial involving cadonilimab, a novel monotherapy for patients suffering from recurrent or metastatic cervical cancer. This study was led by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center and highlighted cadonilimab's exceptional potential in extending survival rates among patients who have previously undergone platinum-containing chemotherapy.

Promising Survival Rates

The findings from the COMPASSION-03 study present a remarkable 24-month overall survival (OS) rate of 100% among those patients who achieved a complete response (CR). With a median follow-up of approximately 26.5 months, this statistic is indeed compelling, contrasting sharply with traditional therapeutic outcomes in similar patient demographics. Notably, in cases of partial response (PR), the 24-month OS rate stood at an impressive 63%.

The significance of these findings cannot be overstated; they suggest that cadonilimab is not merely a stopgap in treatment options but rather offers patients a real chance at long-term remission and improved quality of life. Moreover, the median progression-free survival (PFS) for CR patients remains unreached, which is a promising indicator of cadonilimab's capability to sustain therapeutic benefits over time.

The Role of PD-L1 Expression

Interestingly, the study also addressed the diverse expression of PD-L1 among patients, revealing that cadonilimab maintained efficacy irrespective of PD-L1 status. This point is particularly relevant as previous treatments have often struggled to achieve effectiveness in PD-L1 low/negative populations. With over 18% of the enrolled subjects presenting with low PD-L1 expression, cadonilimab’s ability to deliver a median OS of 17.5 months is groundbreaking. The 18-month and 24-month OS rates of 47.8% and 40.9%, respectively, point to a more inclusive therapeutic reach, potentially redefining treatment standards in advanced cervical cancer.

A New Class of Immunotherapies

Cadonilimab is recognized as the world’s first bispecific antibody cancer immunotherapy officially launched in 2022. Its unique mechanism, targeting both PD-1 and CTLA-4, allows for synergistic anti-tumor activity that outperforms the current standard of care in numerous clinical settings, particularly in challenging cases such as tumors resistant to immunotherapy. This innovative approach effectively circumvents the limitations often observed with singular-target therapies, such as heightened toxicity or inadequate response in difficult-to-treat populations.

Future Directions and Collaborative Efforts

With multiple clinical trials underway and a robust pipeline of more than 50 innovative therapeutic assets, Akeso is well-positioned to capitalize on the success of cadonilimab. The company emphasizes an ongoing commitment to global collaboration, integrating resources to expand market access and further benefit cancer patients worldwide.

In summary, cadonilimab's promising results signify an exciting era in the fight against recurrent and metastatic cervical cancer, potentially heralding a shift in treatment protocols and patient outcomes. As clinical research continues to evolve, therapies like cadonilimab could offer new hope for patients previously facing limited options.